MTPM - MitoPharm to Emphasize its Focus on Promoting Health and Vitality Through Improving the Function of Mitochondrial
MitoPharm Corporation (MTPM) (the "Company") is pleased to announce further to its news release of March 9th, 2007, MitoPharm, on January 2007 announced its merger with HerbalPharm, Inc., a Washington company, changed its name to emphasize its focus on promoting health and vitality through improving the function of mitochondria. Mitochondrial decay is a current and popular theory as a leading cause of aging. www.mitopharm.com
The Company's key products, RESTORADE(TM) and STAMINA SOLUTIONS(TM), contain a proprietary compound that, under scientific research, demonstrated the ability to reverse mitochondrial decay due to aging. Mitochondria are primarily responsible for the cellular conversion of food molecules, in the presese of oxygen, to usable energy as well as for playing vital roles in various metabolic tasks and in cellular generation.
The RESTORADE and STAMINA SOLUTIONS products are the result of over 15 years of research and development at Hong Kong University of Science and Technology (HKUST), a founding shareholder of MitoPharm. The research and development is led by Dr. Robert Ko, Associate Professor of the Biochemistry Department at HKUST, also a founding shareholder of MitoPharm. HKUST is a world-class research university ranked # 60 worldwide by the Newsweek Magazine.
About the Company
MitoPharm Corporation is a biotechnology company in the research & development, marketing and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly discovered compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST"). At HKUST, scientific studies have identified biochemical actions of MitoPharm's key Compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the Compound from other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain. www.ust.hk
MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active. With its products (to be marketed under MITOPHARM(TM)) MitoPharm believes that it is positioned to become an important producer and supplier in the biotech products industry. www.mitopharm.com
Forward-Looking Statements
This news release includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the Company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) our ability to obtain contracts with suppliers of raw materials and distributors of our products; (2) the risks inherent in the mutual performance of such supplier and distributor contracts (including our production performance); (3) our ability to protect and defend our proprietary technology; (4) our ability to secure and retain management capable of managing growth; (5) our ability to raise necessary financing to execute the Company's business plans; and (6) the our ability to comply with all applicable federal, state and local government and international rules and regulations.
Mogul IR
Robert Adams, 713-401-9333
radams@mogulir.com
Source: Business Wire (May 8, 2007 - 8:12 AM EDT)
News by QuoteMedia
www.quotemedia.com
News 
Market Data 
Discover 
